Abstract
Cystic neoplasms of the pancreas account for about 10% of pancreatic tumors. Intraductal papillary mucinous neoplasms (IPMNs) are the most common cystic tumors of the pancreas presenting with no or unspecific clinical symptoms. Diagnosis of IPMNs is challenging and accomplished by CT, MRI, MRCP and EUS. Primarily, IPMNs are regarded as benign cystic lesions, however, almost 60% of resected IPMNs reveal malignant or invasive growth. The risk to progress to malignancy varies between 20-90% strongly depending on the origin of the lesion (main-duct type, branch-duct type) and clinico-pathological characteristics. Recently, first standardized algorithms for the treatment of IPMNs have been formulated, however, therapeutic consequences (surgical approach vs. surveillance strategy) are still controversial. This review provides a detailed overview of the currently discussed options for diagnostics, therapy and surveillance of IPMNs.
Keywords: IPMN, cystic lesions of the pancreas, precursor of pancreatic cancer, pancreatic cancer
Current Cancer Therapy Reviews
Title: Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer
Volume: 6 Issue: 3
Author(s): Albrecht Neesse, Patrick Michl, Marc Kalinowski, Peter J. Barth, Detlef K. Bartsch, Volker Ellenrieder and Thomas M. Gress
Affiliation:
Keywords: IPMN, cystic lesions of the pancreas, precursor of pancreatic cancer, pancreatic cancer
Abstract: Cystic neoplasms of the pancreas account for about 10% of pancreatic tumors. Intraductal papillary mucinous neoplasms (IPMNs) are the most common cystic tumors of the pancreas presenting with no or unspecific clinical symptoms. Diagnosis of IPMNs is challenging and accomplished by CT, MRI, MRCP and EUS. Primarily, IPMNs are regarded as benign cystic lesions, however, almost 60% of resected IPMNs reveal malignant or invasive growth. The risk to progress to malignancy varies between 20-90% strongly depending on the origin of the lesion (main-duct type, branch-duct type) and clinico-pathological characteristics. Recently, first standardized algorithms for the treatment of IPMNs have been formulated, however, therapeutic consequences (surgical approach vs. surveillance strategy) are still controversial. This review provides a detailed overview of the currently discussed options for diagnostics, therapy and surveillance of IPMNs.
Export Options
About this article
Cite this article as:
Neesse Albrecht, Michl Patrick, Kalinowski Marc, J. Barth Peter, K. Bartsch Detlef, Ellenrieder Volker and M. Gress Thomas, Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698197
DOI https://dx.doi.org/10.2174/157339410791698197 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Genetically Modified Dendritic Cells for Cancer Immunotherapy
Current Gene Therapy Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Patent Selections
Recent Patents on Biomarkers Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Erythropoietin in Cancer: An Update
Current Molecular Medicine First Phase Insulin Secretion and Type 2 Diabetes
Current Molecular Medicine Cholecystokinin 1(A) Receptor Polymorphisms
Current Topics in Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets Podocyte Mitosis – A Catastrophe
Current Molecular Medicine Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry CD93: Recent Advances and Implications in Disease
Current Drug Targets Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy